Literature DB >> 28232409

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Helen E Jo1,2, Ian Glaspole3,4, Christopher Grainge5, Nicole Goh3,6, Peter M A Hopkins7, Yuben Moodley8, Paul N Reynolds9, Sally Chapman9, E Haydn Walters10, Christopher Zappala11, Heather Allan12, Gregory J Keir13, Andrew Hayen14, Wendy A Cooper14, Annabelle M Mahar15, Samantha Ellis15, Sacha Macansh12, Tamera J Corte1,2.   

Abstract

7The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28232409     DOI: 10.1183/13993003.01592-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  53 in total

1.  Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.

Authors:  Gaohong Sheng; Peng Chen; Yanqiu Wei; Huihui Yue; Jiaojiao Chu; Jianping Zhao; Yihua Wang; Wanguang Zhang; Hui-Lan Zhang
Journal:  Chest       Date:  2019-11-12       Impact factor: 9.410

Review 2.  Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?

Authors:  Conal Hayton; Nazia Chaudhuri
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

3.  Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study.

Authors:  Tanzira Zaman; Teng Moua; Eric Vittinghoff; Jay H Ryu; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2020-02-19       Impact factor: 9.410

4.  Familial pulmonary fibrosis: a world without frontiers.

Authors:  Raphael Borie; Bruno Crestani
Journal:  J Bras Pneumol       Date:  2019-10-07       Impact factor: 2.624

5.  Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Kensuke Kataoka; Masahiko Ando; Shinichi Arizono; Akira Morino; Koichi Nishimura; Tomoya Ogawa; Akira Shiraki; Fumiko Watanabe; Ryo Kozu; Takashi Ogura; Yasuhiro Kondoh
Journal:  ERJ Open Res       Date:  2021-08-23

6.  Risk factors for the development of idiopathic pulmonary fibrosis: A review.

Authors:  Tanzira Zaman; Joyce S Lee
Journal:  Curr Pulmonol Rep       Date:  2018-10-16

7.  Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.

Authors:  Bryan T Kelly; Viengneesee Thao; Timothy M Dempsey; Lindsey R Sangaralingham; Stephanie R Payne; Taylor T Teague; Teng Moua; Nilay D Shah; Andrew H Limper
Journal:  BMC Pulm Med       Date:  2021-07-17       Impact factor: 3.317

Review 8.  Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution.

Authors:  Anna Valeria Samarelli; Roberto Tonelli; Irene Heijink; Aina Martin Medina; Alessandro Marchioni; Giulia Bruzzi; Ivana Castaniere; Dario Andrisani; Filippo Gozzi; Linda Manicardi; Antonio Moretti; Stefania Cerri; Riccardo Fantini; Luca Tabbì; Chiara Nani; Ilenia Mastrolia; Daniel J Weiss; Massimo Dominici; Enrico Clini
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

9.  Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.

Authors:  Keishi Sugino; Hirotaka Ono; Natsumi Watanabe; Masahiro Ando; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

10.  Outcomes of Idiopathic Pulmonary Fibrosis Improve with Obesity: A Rural Appalachian Experience.

Authors:  Rahul G Sangani; Andrew J Ghio; Hasan Mujahid; Zalak Patel; Kristen Catherman; Sijin Wen; John E Parker
Journal:  South Med J       Date:  2021-07       Impact factor: 0.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.